Comparative Pharmacology
Head-to-head clinical analysis: HYDROCHLOROTHIAZIDE INTENSOL versus INDERIDE 80 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCHLOROTHIAZIDE INTENSOL versus INDERIDE 80 25.
HYDROCHLOROTHIAZIDE INTENSOL vs INDERIDE-80/25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits sodium-chloride symporter in distal convoluted tubule, reducing sodium and chloride reabsorption and increasing water excretion.
INDERIDE-80/25 is a combination of propranolol (a non-selective beta-adrenergic receptor antagonist) and hydrochlorothiazide (a thiazide diuretic). Propranolol blocks beta-1 and beta-2 adrenergic receptors, reducing heart rate, myocardial contractility, and renin release, thereby lowering blood pressure. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the kidney, increasing excretion of sodium, chloride, and water, reducing plasma volume.
25-100 mg orally once daily or in divided doses. Titrate based on response; maximum 200 mg/day.
One tablet (80 mg propranolol/25 mg hydrochlorothiazide) orally twice daily.
None Documented
None Documented
Terminal half-life 6–15 hours (mean ~10 hours); prolonged in renal impairment (creatinine clearance <30 mL/min) and elderly.
Propranolol: 3-6 hours (single dose), prolonged with chronic dosing (up to 12 hours). Hydrochlorothiazide: 6-15 hours; prolonged in renal impairment.
Primarily renal (≥95% as unchanged drug); negligible biliary/fecal elimination (<5%).
Renal: 40% unchanged propranolol; 60% as metabolites. Biliary/fecal: minimal (less than 1%). Hydrochlorothiazide: renal 95% unchanged.
Category A/B
Category C
Thiazide Diuretic
Beta Blocker and Thiazide Diuretic